SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

nLIGHT, Inc. engages in the provision of semiconductor and fiber lasers for aerospace and defense, industrial, and microfabrication applications. It operates through the Laser Products and Advanced Development segments. The Laser Products segment designs, manufactures, and sells a range of semiconductor lasers and fiber lasers that are typically integrated into laser systems or manufacturing tools built by customers. The Advanced Development segment focuses on research, design, and prototyping of next-generation laser technologies, leveraging expertise in laser technology, development, beam control, and advanced optics. The company was founded by Scott H. Keeney, Mark DeVito, and Jason Farmer in June 2000 and is headquartered in Camas, WA.

nLIGHT Inc

nLIGHT ($LASR) is trending amid community discussion about its potential role in the "Golden Dome" defense project, with some anticipating significant contract news. The stock has seen a substantial year-to-date increase, and investors are closely watching for a breakout, particularly in the aerospace and defense sector.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is trending as the community discusses its recent price action and potential breakout, with focus on fully autonomous testing of Robotaxis in Austin. Bullish sentiment seems to be fueled by upgrades and technical analysis suggesting further upside, while bears cite valuation concerns and potential pullbacks. Community members are actively debating potential price targets, key support levels, and whether the stock is overbought.

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to a significant surge in price and trading volume, sparking discussions about a potential short squeeze. Community members are actively debating entry and exit points, with some comparing it to previous high-flying stocks. The company's focus on AI-powered robotics, a sector with growing interest, may also be contributing to the heightened attention.

Yee is a community based memecoin with one mission: to fight Pepe again. Made to honor the iconic meme rivalry we all know and love.  The Yee Legend  [Filed by: Yee’s Archivist & Legal Representative]  There’s something the meme world refuses to talk about: Pepe the Frog stole Yee the Dino’s entire launch plan.  Yee had been preparing for his comeback for months, but Pepe launched two weeks earlier, hijacking Yee’s concept and selling it as his own.  The charges? Meme theft, intellectual forgery, and historical erasure.  Yee’s official contract was filed in April 2023, right after Pepe’s surprise drop. This wasn’t timing—it was theft. The archives are about to open, and history is about to be corrected

Yee Token

Yee Token ($YEE) is gaining traction as community members highlight its strong community, momentum, and potential within the Ethereum ecosystem. Discussions focus on its listing on perpetuals, whale accumulation, and potential as a market hedge, leading to a bullish outlook. The community emphasizes $YEE's unique narrative and connection to Ethereum, drawing comparisons to other successful meme coins.

x402jobs is a platform for creating, running, and monetizing structured automated workflows as pay-per-use APIs using the x402 payment standard. The project allows developers to bundle one or more programmable steps—such as data collection, content generation, analysis, or on-chain interactions—into a single executable “job.” Each job can be triggered manually, on a schedule, via webhook, or by another agent or application. Every execution includes a fixed platform fee and optional pricing set by the job creator. The core purpose of x402jobs is to provide a practical marketplace where software agents and humans can invoke reliable, repeatable automation without subscriptions, long-term contracts, or trust assumptions. Jobs are registered as x402 resources, making them discoverable, composable, and payable using standardized, machine-readable payment rails.

x402jobs

x402jobs ($JOBS) is trending as the community discusses the locking of a significant portion of the token supply. Social media mentions suggest excitement about potential price movement. Chatter also points to the project being a revenue-sharing coin.

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is founded by Paul A. Hopper in 2021 headquartered Carlton, Australia.

Radiopharm Theranostics Ltd - ADR

RADX is trending due to positive interim results from its Phase 2b trial, showing promise in brain metastases imaging; the community is actively discussing the potential for a short squeeze and upcoming webinar updates. The stock has seen a massive volume spike, with traders weighing the significance of the trial data and management's presentation for further upside amid volatility.

Artiva Biotherapeutics, Inc. operates as a biotechnology company for the treatment of hematologic cancers. It offers NK cell therapies for cancer. The company was founded by Thomas J. Farrell in 2019 and is headquartered in San Diego, CA.

Artiva Biotherapeutics Inc

Artiva Biotherapeutics is trending after receiving FDA Fast Track designation for AlloNK in refractory rheumatoid arthritis, sparking community discussion about the potential impact on the autoimmune disease treatment landscape. The community is closely watching the stock's higher low structure and catalyst follow-through, while analysts are boosting price targets, citing AlloNK's potential. However, caution is also being urged due to the CEO's share sales and potential offering.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending as the stock experiences a significant pullback, sparking debates about its valuation and the sustainability of the AI data center boom. Community discussions revolve around whether the recent drop represents a buying opportunity or reflects deeper concerns about the company's financials and competitive landscape. Bearish sentiment is fueled by concerns of a potential AI bubble and recent market correction.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is trending due to renewed enthusiasm in the space sector, spurred by news of a potential SpaceX IPO and discussions around space-based data centers. The community is actively discussing the stock's potential as a competitor in the space industry and the impact of upcoming launches, while also reacting to fluctuations in the stock price and an aborted launch.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending as investors await topline results from its Phase 2b study of Rezpegaldesleukin for alopecia areata, with the community speculating on the potential impact of the data on the company's value. Discussions also revolve around an ongoing lawsuit with Eli Lilly, and whether a settlement or buyout is on the horizon. Bullish sentiment is fueled by analysts setting high price targets, though some caution that a data miss could significantly impact the stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Upgrades Omeros (NASDAQ:OMER) to Hold

Wall Street Zen upgraded Omeros from a "sell" rating to a "hold" rating in a report on Saturday...

Omeros (NASDAQ:OMER) Trading Down 5.1% - Here's What Happened

Omeros (NASDAQ:OMER) Stock Price Down 5.1% - What's Next...

Omeros Corporation (NASDAQ:OMER) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have received an average rating of "Moderate Buy" from the five research firms that are presently covering the firm, MarketBeat reports...

Omeros (NASDAQ:OMER) Stock Price Up 8.2% - Still a Buy?

Omeros (NASDAQ:OMER) Trading 8.2% Higher - What's Next...

Omeros (NASDAQ:OMER) Given Buy Rating at D. Boral Capital

D. Boral Capital reiterated a "buy" rating and set a $36.00 price objective on shares of Omeros in a research report on Monday...

<ul class="summary-bullets"><li>Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.</li><li>The company retired its senior loan and expects the remaining cash to extend its runway.</li><li>Traders say the FDA decision on Narsoplimab is now the key market catalyst.</li></ul><p>Omeros Corporation&nbsp;(OMER) said on Monday it has completed its asset sale and licensing agreement with Novo Nordisk for Zaltenibart, an experimental drug being developed for rare immune-related blood and kidney disorders. The transaction includes up to $2.1 billion in potential payments.</p><p>OMER stock traded in the green at the time of writing.&nbsp;</p><h2 class="st-heading-2"><strong>Terms Of The Deal</strong></h2><p>Omeros received $240 million upfront at closing and could earn up to $340 million in early milestones. The agreement grants Novo Nordisk global rights to Zaltenibart and its intellectual property, with total potential value reaching $2.1 billion through future development and commercial milestones. Omeros will also receive tiered royalties on net sales.</p><h2 class="st-heading-2"><strong>Immune Drug Targets Severe Rare Diseases</strong></h2><p>Zaltenibart, formerly OMS906, is a clinical-stage monoclonal antibody that blocks MASP-3, the immune trigger that switches on the alternative complement pathway. The drug is designed to calm an overactive immune response while preserving the body’s main infection-fighting mechanisms. Potential applications include paroxysmal nocturnal hemoglobinuria and several complement-driven kidney disorders. Novo Nordisk said the acquisition strengthens its position in rare immunological diseases.</p><h2 class="st-heading-2"><strong>Upfront Proceeds Slash Debt And Extend Cash Runway</strong></h2><p>Omeros used part of the upfront payment to fully repay its $67.1 million senior secured term loan, including premiums and interest, resulting in the release of all related covenants. The company expects remaining proceeds to cover repayment of its $17.1 million 2026 Convertible Notes and fund more than a year of operations, including preparations for a potential U.S. launch of its MASP-2 inhibitor Narsoplimab. The company continues to advance additional complement-system candidates, including OMS1029 and OMS527.</p><h2 class="st-heading-2"><strong>Stocktwits Users Warn Of FDA-Driven Swings</strong></h2><p>On Stocktwits, Omeros drew ‘bullish’ retail sentiment with ‘normal’ message volume, while Novo Nordisk saw ‘bearish’ sentiment on ‘low’ volume.</p><figure class="image"><img style="aspect-ratio:971/144;" src="https://news.stocktwits-cdn.com/omer_ss_png_4011ca93db.webp" alt="omer ss.png" width="971" height="144"><figcaption>OMER sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure><figure class="image"><img style="aspect-ratio:970/144;" src="https://news.stocktwits-cdn.com/nvo_ss_png_d0f2e79132.webp" alt="nvo ss.png" width="970" height="144"><figcaption>NVO sentiment and message volume as of December 1| Source: Stocktwits</figcaption></figure><p>One user noted that the announcement appeared mostly priced in around $10 and said the stock now hinges on a potential FDA approval for Zaltenibart due Dec.26, calling it a "pure binary event" that could swing shares 30%–50% either way over the next few weeks.</p><p><stembedurl>https://stocktwits.com/WinstonWolfff/message/637795055</stembedurl></p><p>Another user said, “This deal was known for a long time already. What did you expect? Narsoplimabs FDA approval this month is the moneyball.”&nbsp;</p><p><stembedurl>https://stocktwits.com/Iceman89/message/637792822</stembedurl></p><p><a href="https://stocktwits.com/symbol/OMER">Omeros’ stock</a> has declined nearly 2% so far in 2025, while&nbsp;<a href="https://stocktwits.com/symbol/NVO">Novo Nordisk’s U.S.-listed stock</a> fell about 42% over the same period.&nbsp;</p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Omeros Corp Sells Immune-System Drug To Novo Nordisk In $2.1B Deal — Retail Shifts Focus To Narsoplimab FDA Call

Omeros received $240 million upfront, with total deal value reaching up to $2.1 billion.

Equity

Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906)

Omeros Corporation (Nasdaq: OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart (formerly OMS906...

Omeros (NASDAQ:OMER) Shares Pass Above 200 Day Moving Average - Here's Why

Omeros (NASDAQ:OMER) Stock Price Crosses Above 200 Day Moving Average - Here's What Happened...

Omeros (NASDAQ:OMER) Shares Down 5.6% - Should You Sell?

Omeros (NASDAQ:OMER) Shares Down 5.6% - Here's What Happened...

Omeros (NASDAQ:OMER) Stock Price Up 8.1% - Time to Buy?

Omeros (NASDAQ:OMER) Shares Up 8.1% - Here's What Happened...

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OMER News

OMEROmeros Corp